FDA declines to grant accelerated approval for experimental Alzheimer’s treatment

The US Food and Drug Administration declined to grant accelerated approval to an experimental Alzheimer’s drug, donanemab, and requested additional data from Eli Lilly and Company, the drug maker.

(SOURCE) https://www.cnn.com/2023/01/20/health/alzheimers-drug-donanemab-fda-eli-lilly/index.html

Share:


Related Posts

The latest sign Democrats face a daunting midterm year

• Opinion: One problem in Biden’s first year • Battered White House searches...

3 reasons it's not too late to refinance your mortgage

Share this (SOURCE) https://www.cnn.com/2022/01/05/cnn-underscored/money/should-i-refinance-my-mortgage/index.html?iid=CNNUnderscoredHPcontainer

Leave a Comment

Your email address will not be published. Required fields are marked *

Add Comment *

Name *

Email *

Website